Health :: Management of deep vein thrombosis with heparin
Contrary to oral warfarin therapy, the use of subcutaneous low-molecular weight heparin (LMWH) has the advantage of stable dosing without the need of prothrombin time monitoring. Few randomized studies have compared the efficacy of LMWH with the least costly unfractionated heparin for the treatment of deep vein thrombosis (DVT). In the United States, 6 days of LMWH therapy for an 80 kg patient is estimated to cost $712, compared with $37 of unfractionated heparin.